Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is Aurora Investment Counsel’s 10th Largest Position

Aurora Investment Counsel increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 0.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 54,698 shares of the company’s stock after purchasing an additional 232 shares during the quarter. Amphastar Pharmaceuticals makes up about 1.4% of Aurora Investment Counsel’s holdings, making the stock its 10th biggest position. Aurora Investment Counsel’s holdings in Amphastar Pharmaceuticals were worth $2,654,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in AMPH. Segall Bryant & Hamill LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at $921,000. Quest Partners LLC increased its holdings in Amphastar Pharmaceuticals by 74.4% during the third quarter. Quest Partners LLC now owns 7,586 shares of the company’s stock worth $368,000 after buying an additional 3,237 shares during the last quarter. Cornercap Investment Counsel Inc. bought a new stake in Amphastar Pharmaceuticals in the third quarter worth about $263,000. Chase Investment Counsel Corp boosted its stake in Amphastar Pharmaceuticals by 45.0% in the third quarter. Chase Investment Counsel Corp now owns 29,000 shares of the company’s stock valued at $1,407,000 after acquiring an additional 9,000 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in shares of Amphastar Pharmaceuticals by 10.9% during the 3rd quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock valued at $10,605,000 after acquiring an additional 21,530 shares during the period. 65.09% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the transaction, the director now directly owns 75,409 shares in the company, valued at approximately $3,504,256.23. This trade represents a 3.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Rong Zhou sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the sale, the executive vice president now directly owns 118,388 shares in the company, valued at $5,724,059.80. This trade represents a 3.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 31,533 shares of company stock worth $1,571,652 in the last quarter. 27.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Trading Up 1.1 %

NASDAQ:AMPH opened at $44.09 on Thursday. The company has a market cap of $2.12 billion, a P/E ratio of 14.70, a P/E/G ratio of 0.89 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The stock’s fifty day moving average price is $48.38 and its two-hundred day moving average price is $44.42.

Wall Street Analysts Forecast Growth

AMPH has been the topic of several research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Finally, StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.